Findings
depression
In this randomized clinical trial of 30 patients with fluctuating antidepressant response, more patients who received a single subanesthetic dose of esketamine experienced a reduction of depression severity by at least 50% compared with patients who received midazolam, The difference remained statistically significant at the final follow-up at 6 weeks.